Interestingly, structural analyses of non-catalytic domains of TKs have revealed unique modes of kinase regulation [37], which resulted in the development of allosteric inhibitors with improved anti-tumor activities, as reported for asciminib in chronic myeloid leukemia [38]. This evidence concerns the gene CDC42 and neoplasm.